Newal R&D

Newal R&D is a London-based biotechnology company specializing in the development of synthetic ezrin peptides to address chronic inflammation, viral diseases, and longevity. The company's platform is based on Human Ezrin Peptide One (HEP1), marketed as Gepon in Russia, and its third-generation derivative, RepG3, which function as immunomodulators by amplifying adaptive immunity and suppressing pro-inflammatory cytokines. Newal R&D has gained traction through experimental treatment programs for Long COVID and COVID-19 vaccine injury, utilizing inhaled and oral delivery methods. Their research extends to treating drug-resistant infections and supporting healthy aging by targeting the RANTES/CCL5 signaling pathways. The company collaborates with international institutions, including the National Physical Laboratory and the Institute of Immunology in Moscow, to advance its peptide-based therapeutic pipeline.